Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1252851710 | 12528517 | 10 | F | 20160909 | 20160705 | 20160912 | EXP | CA-PFIZER INC-2016317758 | PFIZER | 75.00 | YR | M | Y | 0.00000 | 20160912 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1252851710 | 12528517 | 1 | SS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, WEEKLY | 0 | 50 | MG | /wk | |||||||
| 1252851710 | 12528517 | 2 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | UP TO 25MG, WEEKLY | 11719 | /wk | |||||||||
| 1252851710 | 12528517 | 3 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 1 G, 2X/DAY | 7073 | 1 | G | BID | |||||||
| 1252851710 | 12528517 | 4 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | 200 MG, 2X/DAY | 0 | 200 | MG | BID | ||||||||
| 1252851710 | 12528517 | 5 | SS | ARAVA | LEFLUNOMIDE | 1 | 20 MG, DAILY | 0 | 20 | MG | |||||||||
| 1252851710 | 12528517 | 6 | SS | RITUXAN | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 1 G, UNK | 0 | 1 | G | ||||||||
| 1252851710 | 12528517 | 7 | SS | GOLD | GOLD | 1 | UNK | 0 | |||||||||||
| 1252851710 | 12528517 | 8 | SS | IMURAN | AZATHIOPRINE | 1 | 150 MG, 3X/DAY | 0 | 150 | MG | TID | ||||||||
| 1252851710 | 12528517 | 9 | SS | NEORAL | CYCLOSPORINE | 1 | 125 MG, 2X/DAY | 0 | 125 | MG | BID | ||||||||
| 1252851710 | 12528517 | 10 | C | PREDNISONE. | PREDNISONE | 1 | 10 MG, DAILY | 0 | 10 | MG | |||||||||
| 1252851710 | 12528517 | 11 | C | CELEXA | CITALOPRAM HYDROBROMIDE | 1 | 40 MG, DAILY | 0 | 40 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 1252851710 | 12528517 | 1 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 2 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 3 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 4 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 5 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 6 | Rheumatoid arthritis |
| 1252851710 | 12528517 | 7 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 1252851710 | 12528517 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 1252851710 | 12528517 | Leukopenia | |
| 1252851710 | 12528517 | Pruritus | |
| 1252851710 | 12528517 | Rash | |
| 1252851710 | 12528517 | Squamous cell carcinoma of skin | |
| 1252851710 | 12528517 | Treatment failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 1252851710 | 12528517 | 6 | 201508 | 0 |